摘要
用蚓激酶治疗心肌梗死合并高纤维蛋白原血症４３ 例，分别于用药前、用药后测定血纤维蛋白原。发现用蚓激酶２ 周后，血纤维蛋白原质量浓度明显下降〔（４ ．３３ ±１ ．０９） ｇ／Ｌ〕，与用药前〔（５ ．３４ ±０ ．８９） ｇ／Ｌ〕相比有显著性差异（ Ｐ＜ ０ ．０５） 。用药３ 周后纤维蛋白原进一步降低〔（３ ．７１ ±０ ．４８） ｇ／Ｌ〕，与用药前和用药后２ 周相比均有显著性差异（ 均Ｐ＜ ０ ．０５） 。用药后２ 周和３ 周，蚓激酶组与对照组相比亦有显著性差异（ 均Ｐ＜ ０ ．０５） ，且无明显不良反应。结果提示蚓激酶治疗高纤维蛋白原血症有一定疗效，可以考虑做为冠心病的预防用药。
The aim of this study is to evaluate the effects of lumbrokinase on hyperfibrinogenemia . Patients with hyperfibrinogenemia were orally ad ministered lum brokinase six tablets per day for three weeks.Seru m fibrinogen level was examined before and after treatment. Compared with the control groups which were given antilipemia or (and) antiplatelet aggregation drugs , serum fibrinogen inlumbrokinase treated group significantly decreased two weeks after treatment in a time related manner 〔Before treatment (5 .34 ±0 .89) g/L,two weeks aftertreatment (4 .33 ±1 .09) g/L,three weeks after treatment ( 3 . 71 ±0 . 48 ) g/L〕. These results showed that lumbrokinase could relieve hyperfibrinogenemia,therefore the formation of thrombi would be decreased . Lum brokinase which had less side effects could be considered as a preventive drug of coronary atherogenesis disease .
出处
《首都医科大学学报》
CAS
1999年第4期264-265,共2页
Journal of Capital Medical University
关键词
纤维蛋白原血症
蚓激酶胶囊
心肌梗死
药物疗法
coronary atherogenesis disease (CAD)
hyperfibrinogenemia
lu mbrokinase capsule
